Astera Labs (NASDAQ:ALAB) Upgraded to Outperform at Northland Securities

Northland Securities upgraded shares of Astera Labs (NASDAQ:ALAB) from a market perform rating to an outperform rating in a report published on Monday morning, Marketbeat Ratings reports. Northland Securities currently has $175.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on the company. Needham & Company LLC boosted their price objective on Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. CICC Research started coverage on Astera Labs in a report on Friday, August 29th. They set an “outperform” rating and a $190.00 price target for the company. Zacks Research downgraded Astera Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Cowen reaffirmed a “hold” rating on shares of Astera Labs in a report on Wednesday, November 5th. Finally, Bank of America began coverage on Astera Labs in a research report on Friday, October 3rd. They set a “neutral” rating and a $230.00 price objective on the stock. Fourteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Astera Labs presently has an average rating of “Moderate Buy” and an average price target of $184.82.

Astera Labs Price Performance

NASDAQ:ALAB opened at $141.39 on Monday. The company has a market cap of $23.88 billion, a P/E ratio of 127.38, a P/E/G ratio of 2.69 and a beta of 1.38. The firm’s fifty day moving average price is $192.00 and its two-hundred day moving average price is $144.85. Astera Labs has a one year low of $47.13 and a one year high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The company had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. During the same quarter last year, the company posted $0.23 EPS. Astera Labs’s quarterly revenue was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, equities research analysts expect that Astera Labs will post 0.34 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Manuel Alba sold 183,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $173.27, for a total transaction of $31,708,410.00. Following the sale, the director directly owned 385,863 shares of the company’s stock, valued at approximately $66,858,482.01. This represents a 32.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $192.16, for a total value of $1,921,600.00. Following the completion of the transaction, the general counsel owned 151,573 shares in the company, valued at $29,126,267.68. The trade was a 6.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 225,500 shares of company stock worth $39,531,460 in the last 90 days. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Astera Labs

A number of large investors have recently bought and sold shares of the company. Alliancebernstein L.P. increased its holdings in Astera Labs by 114.2% in the 1st quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock valued at $501,289,000 after buying an additional 4,478,741 shares during the period. Atreides Management LP boosted its position in shares of Astera Labs by 153.3% during the 1st quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock worth $277,601,000 after acquiring an additional 2,815,614 shares in the last quarter. Vanguard Group Inc. increased its stake in Astera Labs by 29.6% in the second quarter. Vanguard Group Inc. now owns 12,049,223 shares of the company’s stock valued at $1,089,491,000 after acquiring an additional 2,751,747 shares during the last quarter. Amundi increased its stake in Astera Labs by 1,298.6% in the third quarter. Amundi now owns 1,421,263 shares of the company’s stock valued at $278,283,000 after acquiring an additional 1,319,643 shares during the last quarter. Finally, FengHe Fund Management Pte. Ltd. acquired a new position in Astera Labs during the second quarter valued at approximately $106,772,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.